Bosentan

Bibliography

• Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:7S-10S
   PubMed Web of Science ®Google Scholar
• Badesch DB, Champion HC, Sanchez MAG, Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-66
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-31
   PubMed Web of Science ®Google Scholar
• Rich S, Danzker DR, Ayres SM, Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, Pulmonary arterial hypertension in France – results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30
   PubMed Web of Science ®Google Scholar
• The International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-4
   PubMedGoogle Scholar
• Deng Z, Morse JH, Slager SL, Familial primary pulmonary hypertension (Gene PPH1) is caused by mutation in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;26:737-44
   Google Scholar
• Newman JH, Wheeler L, Lane KB, Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-24
   PubMed Web of Science ®Google Scholar
• Thompson JR, Machado RD, Pauciulo MW, Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPr-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-5
   PubMedGoogle Scholar
• Atkinson C, Stewart S, Upton PD, Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-8
   PubMed Web of Science ®Google Scholar
• Machado RD, Pauciulo MW, Thomson JR, BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68:92-102
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galiè N, Rubin LJ, Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, ACCF/AHA 2009 Expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation 2009;119:2250-94
   PubMed Web of Science ®Google Scholar
• Simmoneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54
   PubMedGoogle Scholar
• Sitbon O, Humbert M, Ioos V, Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? Am J Respir Crit Care Med 2003;167:A440
   Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galiè N, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension – a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• Tapson VF, Gombert-Maitland M, McLaughlin VV, Safety and efficacy of IV treprostinil for pulmonary arterial hypertension. A prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-8
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• Galiè N, Beghetti M, Gatzoulis MA, Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54
   PubMed Web of Science ®Google Scholar
• Galiè N, Badesch D, Oudiz R, Ambrisentan therapy for pulmonary arterial hypertension. J Am Cardiol Coll 2005;46:529-35
   PubMed Web of Science ®Google Scholar
• Galiè N, Olschewski H, Oudiz R, Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15
   PubMed Web of Science ®Google Scholar
• Wallace BA, Janes RW. The crystal structure of human endothelin-1 and how it relates to receptor binding. J Cardiovasc Pharmacol 1995;26:S250-3
   PubMedGoogle Scholar
• Sakurai T, Yanagisawa M, Inoue A, cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 1991;175:44-7
   PubMed Web of Science ®Google Scholar
• Janakidevi K, Fisher MA, Del Vecchio PJ, Endothelin-1 stimulated DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992;263:C1295-301
   PubMed Web of Science ®Google Scholar
• D'Orléans-Juste P, Labonté J, Bkaily G, Function of endothelinB receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 2002;95:221-38
   PubMed Web of Science ®Google Scholar
• Packer R, Stanek B, Hülsmann M, Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41
   PubMed Web of Science ®Google Scholar
• Krum H, Goldsmith R, Wilshire-Clement M, Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995;75:1282-3
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Vancheeswaran R, Dashwood MR, Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151:831-41
   PubMed Web of Science ®Google Scholar
• Bauer M, Wilkens H, Langer F, Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-6
   PubMed Web of Science ®Google Scholar
• Levin ER. Endothelins. N Engl J Med 1995;333:356-63
   PubMed Web of Science ®Google Scholar
• Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007;47:1-29
   PubMedGoogle Scholar
• Soma S, Takahashi H, Muramatsu M, Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol 1999;20:620-30
   PubMedGoogle Scholar
• Takahashi H, Soma S, Muramatsu M, Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 2001;18:5-14
   PubMedGoogle Scholar
• Clozel M, Breu V, Burri K, Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-61
   PubMed Web of Science ®Google Scholar
• Clozel M, Breu V, Gray GA, Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonists. J Pharmacol Exp Ther 1994;27:228-35
   Google Scholar
• Weber C, Schmitt R, Birnboeck H, Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60:124-37
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet 2001;358:1119-23
   PubMed Web of Science ®Google Scholar
• Sitbon O, Badesch DB, Channick RN, Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE, Barst RJ, Ayres SM, Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9
   PubMed Web of Science ®Google Scholar
• Sitbon O, McLaughlin VV, Badesch DB, Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with a historical cohort of patients started on intravenous epoprostenol. Thorax 2005;60:1025-30
   PubMed Web of Science ®Google Scholar
• Galiè N, Rubin LJ, Hoeper MM, Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008;371:2093-100
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Ivy DD, Widlitz A, Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:697-704
   PubMed Web of Science ®Google Scholar
• Benza RL, Rayburn BK, Tallaj JA, Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 2006;129:1009-15
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Beghetti M, Galiè N, Longer-term bosentan therapy improves functional capacity in Einsenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008;127:27-32
   PubMed Web of Science ®Google Scholar
• Sitbon O, Gressin V, Speich R, Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-17
   PubMed Web of Science ®Google Scholar
• Ergul A, Grubbs AL, Zhang Y, Expression and activity of pulmonary endothelin converting enzyme in heart failure: relation to endothelin biosynthesis and receptor distribution. J Card Fail 2001;7:84-91
   PubMedGoogle Scholar
• Lüscher TF, Enseleit F, Pacher R, Hemodynamic and neurohormonal effects of selective endothelin A (ETA) receptor blockade in chronic heart failure – the Heart Failure ETA Receptor Blockade Trial (HEAT). Circulation 2002;106:2666-72
   PubMed Web of Science ®Google Scholar
• Cohn JN. Sympathetic nervous system in heart failure. Circulation 2002;106:2417-18
   PubMedGoogle Scholar
• Cohn JN, Levine TB, Olivari MT, Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23
   PubMed Web of Science ®Google Scholar
• Huntington K, Picard P, Moe G, Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure. J Cardiovasc Pharmacol 1998;31:S424-6
   PubMedGoogle Scholar
• Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007;28:233-41
   PubMed Web of Science ®Google Scholar
• Grigioni F, Potena L, Galiè N, Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 2006;25:1241-6
   PubMedGoogle Scholar
• Packer M, McMurray J, Massie BM, Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005;11:12-20
   PubMed Web of Science ®Google Scholar
• Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 2002;8:124-7
   PubMed Web of Science ®Google Scholar
• Teerlink JR. Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr Heart Fail Rep 2005;2:191-7
   PubMedGoogle Scholar
• Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-7
   PubMed Web of Science ®Google Scholar
• Perez-Villa F, Cuppoletti A, Rossel V, Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin Transplant 2006;20:239-44
   PubMedGoogle Scholar
• Stolz D, Rasch H, Linka A, A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-28
   PubMed Web of Science ®Google Scholar
• Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009;3:15-21
   PubMedGoogle Scholar
• Günther A, Enke B, Markart P, Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 2007;29:713-19
   PubMed Web of Science ®Google Scholar
• King TE Jr, Behr J, Brown KK, BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AWA, Prins MH, Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64
   PubMed Web of Science ®Google Scholar
• Archibald CJ, Auger WR, Fedullo PF, Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999;160:523-8
   PubMed Web of Science ®Google Scholar
• Blauwet LA, Edwards WD, Tazelaar HD, McGregor CGA. Surgical pathology of pulmonary thromboendarterectomy: a study of 54 cases from 1990 to 2001. Hum Pathol 2003;34:1290-8
   PubMed Web of Science ®Google Scholar
• Jaïs X, D'Armini AM, Jansa P, Bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension study group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-34
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Jais X, Bonderman D, The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006;28:138-43
   PubMed Web of Science ®Google Scholar
• Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005;25:783-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Card Med 2006;174:1257-63
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M, Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4
   PubMed Web of Science ®Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H, Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, and endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 1999;39:703-14
   PubMed Web of Science ®Google Scholar
• Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999;39:847-54
   PubMed Web of Science ®Google Scholar
• Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann Pharmacother 2003;37:1028-31
   PubMed Web of Science ®Google Scholar
• van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006;44:113-18
   PubMed Web of Science ®Google Scholar
• Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;31:1650-7
   PubMed Web of Science ®Google Scholar
• Wrishko RE, Dingemanse J, Yu A, Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008;48:610-18
   PubMed Web of Science ®Google Scholar
• Paul GA, Gibbs JSR, Boobis AR, Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-12
   PubMed Web of Science ®Google Scholar
• Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50
   PubMed Web of Science ®Google Scholar